Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Q1 2023 Earnings Presentation
27 slides from Omnicell's earnings presentation, May 2, 2023
Slide 1: Omnicell Investor Relations
o) Omnicell Investor Relations May 2, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forwardlooking statements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other nor-historical informat
Slide 3: Our Mission and Vision
Our Mission Be the clinician’s most trusted partner for medication management. We are dedicated to continuously deliver innovative technology that helps our customers improve patient care, for everyone. Our Vision Deliver the most compelling automation and services that accelerate pharmacy perfectio
Slide 4: Our Strategy
Our Strategy Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform. = a Point Central of Care Pharmacy INPATIENT Cu Specialty Retail Pharmacy OUTPATIENT Home
Slide 5: Omnicell: Compelling Growth Opportunities
Omnicell: Compelling Growth Opportunities Category creator Leading strategic partner to Resilient, long-term revenue Demonstrated track record of transforming the pharmacy health systems in large and growth accelerated by strong growth built on a platform of care delivery model growing market segmen
Slide 6: The Autonomous Pharmacy Framework — an Industry Vision
The Autonomous Pharmacy Framework — an Industry Vision ed Highly Autonomay Level 2 © 2023 Omnicell, Inc. 6
Slide 7: Our Comprehensive Solutions Fundamentally Deliver Better Healthcare
Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value Central Pharmacy Dispensing Service IV Compounding M Specialty Service ee aN Pharmacy Services Te Inventory Optimization Service Point of © omnicell <5 EnlivenHealth Care |= Connected Intelligent Infrastructure Inpatient Outpa
Slide 8: Leader in Large and Growing Segments
Leader in Large and Growing Segments Omnicell is growing its leadership position across a potential $90 Billion+ TAM Estimated TAM Opportunity! $22 Billion Retail $90 Billlon+ TOTAL TAM $19 Billion Point of Care $19 Billion Specialty Pharmacy Services $32 Billion Central Pharmacy
Slide 9: Deep Customer Relationships & Robust Backlog
More than 150 of the top 300 U.S. health systems! in long-term sole-source agreements Robust backlog of $1.215 Billion as of 12/31/2022 Deep Customer Relationships & Robust Backlog Customers increasingly turning to Omnicell for our platform-based approach to medication management Multiple Growth + E
Slide 10: Advanced Services: Accelerating Recurring Revenue Growth
Advanced Services Accelerating Recurring Revenue Growth Advanced Services (% of Total Revenue) Targeting 18% of total revenue for 2023 18% 14% 10% i 2020 2021 2022 2023E NOTE: Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solu
Slide 11: Advanced Services Business Model — Customer Example
Advanced Services Business Model — Customer Example Tech-Enabled Services Model (IVCS and CPDS) YEAR 1 YEAR 2 YEAR 3 YEAR 4-7 Product Revenue End of year 7 R Cash rn Cash Cash TTT ecurring Receiver eceived Received ceiver Advanced received Received Net sales type lease ‘coe m= mm a sre Revenue Recur
Slide 12: Strong Balance Sheet
4) Strong Balance Sheet $2251M Free cash flow projected to grow slower than $1016M $1143M EBITDA as Omnicell reinvests in the Saran $554M transformation to 532M Advanced Services Cash and Cash Equivalents Total Assets Total Equity 19x Liquidity and capital structure support growth strategy Total Deb
Slide 13: Backlog ($Million)
Backlog! ($Million) By type: As of December 31, 2022 As of December 31, 2021 Product Backlog $797 $977 Advanced Services Backlog* $418 $277 Total Backlog $1,215 $1,254 Short-Term Product Backlog $503 $745 Long-Term Product Backlog $294 $232 Short-Term Advanced Services Backlog? $49 $37 Long-Term Adv
Slide 14: Total Year Revenue Composition
Total Year Revenue Composition
Slide 15: Financial Snapshot
Financial Snapshot Qt-2023 Results YoY Change % Total Revenues $291 Million -9% Non-GAAP Gross Margin % 44.8% -410bps Non-GAAP Operating Expenses $117 Million -2% Non-GAAP EBITDA $27 Million -47% Non-GAAP Diluted Earnings Per Share $0.39 -53% See Appendix for a reconciliation of Q+2023 Non-GAAP Gros
Slide 16: 2023 Financial Guidance
2023 Financia Guidance Leadership position in the digital transformation of healthcare with $90 Billion+ TAM2 Bookings! Not Provided $1.000-$1.100 Billion Emerging and scaling of Advanced Total Revenues $278-$288 Million $1.150-$1.190 Billion SENSES GLKSgS Product Revenues $181-$186 Million $740-$76
Slide 17: A Better Way: Our ESG and Innovation Strategy
A Better Way: Our Environment, Social, Governance, and Innovation Strategy @ Environment Innovating for Energy Efficiency Actively contribute to realize 1.5° Celsius future by 2030 Innovation Accelerating for Perfection Design and deliver our products to minimize our environmental footprint while ma
Slide 18: A Better Way: Our Approach to ESG
A Better Way: Our Approach to ESG Our Approach @ Omnicell uses a risk-based approach designed to strategically align our ESG goals and targets to address the risks we believe are most material to our organization Our Better Way @ In 2021, Omnicell identified 11 material topic areas that our internal
Slide 19: MSCI ESG Research Notice
• • • • • • • • • • • • • THE USE BY OMNICELL, INC. OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES (“MSCI”) DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF OMNICELL, INC. BY MSCI. MSCI SER
Slide 20: Omnicell is Positioned to Win
We Expect that Omnicell is Positioned to Win Based on Our Belief that: © © Y Y Omnicell has the right Omnicell is positioned Omnicell is scaling With a track record of solutions and the right as the leading strategic Advanced Services to strong financial business model to partner to health capitaliz
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended March 31, 2023 2022 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues $ 290,629 $ 318,828 Acquisition accounting impact related to deferred revenues
Slide 23: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended March 31, 2023 2022 Reconciliation of GAAP income (loss) from operations to non-GAAP income from operations: GAAP income (loss) from operations $ (22,963) $ 5,084 GAAP
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended March 31, 2023 2022 Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - diluted: Shares - diluted GAAP 44,887 47,918 Shares
Slide 25: Reconciliation of GAAP to Non-GAAP EBITDA
Omnicell, Inc. ‘Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended Three Months Ended Three Months Ended Three Months Ended Year Ended ‘March 31,2023 December 31,2022__S 30,2022 June 30, 2022 December 31,2017 Reconciliation of GAAP n
Slide 26: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage)
Slide 27: Slide 27